# ORM-6151 (BMS-986497)

Source: https://onco.cc/drugs/orm-6151/  
OnCo record `orm-6151` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ORM-6151 (BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped.

## Summary

ORM-6151 (BMS-986497) (ORM-6151, BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics, with Bristol Myers Squibb as acquirer. A CD33-directed antibody carrying a GSPT1-degrading payload, for acute myeloid leukaemia and high-risk MDS. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome. ClinicalTrials.gov registers it in one study linked below. BMS's phase 1 NCT06419634 is TERMINATED ('Inability to meet protocol objectives', 28 August 2026). A Korean news report of 19 September 2026 says BMS discontinued development and returned the rights to Orum. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: ORM-6151; BMS-986497
- Tags: pipeline; ctgov-ingest; discontinued
- Code: ORM-6151
- Modality: Degrader-antibody conjugate
- Mechanism: A CD33-directed antibody carrying a GSPT1-degrading payload, for acute myeloid leukaemia and high-risk MDS.

## Sources

- Orum Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06419634
- Orum Therapeutics: v.daum.net: https://v.daum.net/v/20260919074351390
- ClinicalTrials.gov: trials of ORM-6151: https://clinicaltrials.gov/search?intr=ORM-6151

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- targets: [CD33](https://onco.cc/targets/cd33/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Orum Therapeutics](https://onco.cc/companies/orum-therapeutics/)
- trials: [Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome](https://onco.cc/trials/nct06419634/)

---
JSON: https://onco.cc/api/v1/entities/orm-6151.json